S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
NASDAQ:MDRX

Veradigm (MDRX) Stock Price, News & Analysis

$7.80
-0.01 (-0.13%)
(As of 03/27/2024 ET)
Today's Range
$7.40
$8.15
50-Day Range
$6.13
$9.66
52-Week Range
$5.01
$14.09
Volume
1.84 million shs
Average Volume
10.04 million shs
Market Capitalization
$852.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.25

Veradigm MarketRank™ Stock Analysis

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
44.2% Upside
$11.25 Price Target
Short Interest
Healthy
6.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
0.56mentions of Veradigm in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
11.43%
From $0.70 to $0.78 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.23 out of 5 stars

Business Services Sector

47th out of 299 stocks

Computer Integrated Systems Design Industry

5th out of 36 stocks

MDRX stock logo

About Veradigm Stock (NASDAQ:MDRX)

Veradigm Inc., a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions. The company operates through two segments, Hospitals and Large Physician Practices, and Veradigm. The Hospitals and Large Physician Practices segment provides integrated clinical and financial management solutions, which primarily include EHR-related software; and related installation, support and maintenance, outsourcing, private cloud hosting, and revenue cycle management services. The Veradigm segment offers payer and life sciences solutions, which are primarily targeted at payers, life sciences companies, and other healthcare stakeholders; and software applications for patient engagement and EHR software to single-specialty, and small and mid-sized physician practices, including related clinical, financial, administrative, and operational solutions. Its solutions enable clients to transition, analyze, and coordinate care, and enhance the healthcare delivery across the care community. The company serves physicians, hospitals, governments and militaries, health systems, health plans, life-sciences companies, retail clinics, surgery centers, retail pharmacies, pharmacy benefit managers, insurance companies, employer wellness clinics, consumers, lab companies, urgent care facilities, and venture capital firms, as well as post-acute organizations, such as home health and hospice agencies. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.

MDRX Stock Price History

MDRX Stock News Headlines

my top trade on these 9 tickers
This indicator is uniquely designed to spot the most significant moves in the top stocks out there (and according to our backtesting it has historically nailed these moves with a stunning 90% accuracy). Now, most folks have been saying NVDA is way overbought or overpriced. They didn’t want to “buy at the top” 6 weeks ago… Or again 4 weeks ago… or again 2 weeks ago… And it’s not their fault! That’s what all the talking heads were saying too. But the Apex Indicator would have clearly shown that these were opportunities to buy. And, sure enough, Nvidia slammed through the recommended targets again and again.
MDRX Apr 2024 2.500 put
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Veradigm Completes Acquisition of ScienceIO
Market Whales and Their Recent Bets on MDRX Options
Veradigm Receives Expected Delisting Notice from Nasdaq
Veradigm to Acquire ScienceIO
See More Headlines
Receive MDRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veradigm and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Computer integrated systems design
Sub-Industry
Health Care Technology
Current Symbol
NASDAQ:MDRX
CUSIP
01988P10
Employees
8,000
Year Founded
1986

Price Target and Rating

Average Stock Price Target
$11.25
High Stock Price Target
$13.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+44.2%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.50 billion
Cash Flow
$2.87 per share

Miscellaneous

Free Float
106,758,000
Market Cap
$852.23 million
Optionable
Optionable
Beta
0.62

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. P. Gregory Garrison (Age 70)
    Executive Chairman of the Board
    Comp: $103k
  • Ms. Tejal Vakharia (Age 50)
    Senior VP of Marketing & Government Affairs, General Counsel and Chief Compliance Counsel
    Comp: $1.04M
  • Dr. Shih-Yin Ho M.B.A. (Age 53)
    M.D., Interim Chief Executive Officer & Director
  • Mr. Thomas J. Langan (Age 57)
    President & Chief Commercial Officer
  • Mr. Leland A. Westerfield (Age 54)
    Interim CFO and Principal Financial & Accounting Officer
  • Jenny Gelinas
    Vice President of Investor Relations
  • Mr. Richard Elmore
    Senior Vice President of Corporate Development & Strategy
  • Ms. Lisa Hammond C.P.C. (Age 51)
    Senior VP & Chief Human Resources Officer
  • Mr. John Sage
    Senior Vice President of U.S. Hospitals & Health Systems Sales
  • Mr. Elliot Bryant
    Senior VP & General Manager for Classic Client Solutions Business Unit

MDRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Veradigm stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Veradigm in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MDRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MDRX, but not buy additional shares or sell existing shares.
View MDRX analyst ratings
or view top-rated stocks.

What is Veradigm's stock price target for 2024?

5 brokers have issued 12 month price targets for Veradigm's stock. Their MDRX share price targets range from $10.00 to $13.00. On average, they expect the company's stock price to reach $11.25 in the next year. This suggests a possible upside of 44.2% from the stock's current price.
View analysts price targets for MDRX
or view top-rated stocks among Wall Street analysts.

How have MDRX shares performed in 2024?

Veradigm's stock was trading at $10.49 at the beginning of 2024. Since then, MDRX stock has decreased by 25.6% and is now trading at $7.80.
View the best growth stocks for 2024 here
.

How were Veradigm's earnings last quarter?

Veradigm Inc. (NASDAQ:MDRX) posted its earnings results on Thursday, November, 4th. The software maker reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.09. The software maker had revenue of $369 million for the quarter, compared to the consensus estimate of $376.09 million. The company's revenue was down 8.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.15 EPS.

What ETFs hold Veradigm's stock?
What guidance has Veradigm issued on next quarter's earnings?

Veradigm updated its FY 2023 earnings guidance on Wednesday, January, 10th. The company provided earnings per share (EPS) guidance of 0.790-0.880 for the period, compared to the consensus earnings per share estimate of 0.890. The company issued revenue guidance of $608.0 million-$622.0 million, compared to the consensus revenue estimate of $637.7 million.

What is Paul Black's approval rating as Veradigm's CEO?

796 employees have rated Veradigm Chief Executive Officer Paul Black on Glassdoor.com. Paul Black has an approval rating of 65% among the company's employees.

What other stocks do shareholders of Veradigm own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veradigm investors own include Advanced Micro Devices (AMD), Netflix (NFLX), Energy Transfer (ET), CVS Health (CVS), Ford Motor (F), Himax Technologies (HIMX), Intel (INTC), OPKO Health (OPK), Tesla (TSLA) and Activision Blizzard (ATVI).

Who are Veradigm's major shareholders?

Veradigm's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (13.07%), Vanguard Group Inc. (13.07%), Dimensional Fund Advisors LP (8.22%), Wellington Management Group LLP (5.31%), Pacer Advisors Inc. (2.30%) and Fisher Asset Management LLC (2.07%). Insiders that own company stock include David B Stevens, Elaina Shekhter, Elizabeth Ann Altman, Greg Garrison, Leah Jones, Lisa Khorey, Michael Klayko, Paul Black, Richard J Poulton, Tejal Vakharia and Thomas Langan.
View institutional ownership trends
.

How do I buy shares of Veradigm?

Shares of MDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Veradigm have any subsidiaries?
The following companies are subsidiares of Veradigm: HealthGrid, Practice Fusion, and ZappRx.
Read More
This page (NASDAQ:MDRX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners